Wat is de prijs voor Apexigen, Inc. (APGN)

Het prijs van Apexigen, Inc. (APGN) is $0.385

Wat is de marktkapitalisatie voor Apexigen, Inc. (APGN)

Marktkapitalisatie voorApexigen, Inc. (APGN) is $2.86M

Apexigen, Inc. (APGN) Winst

Apexigen Inc., established in 2010 and based in San Carlos, California, is a clinical-stage biotechnology company dedicated to the discovery and advancement of antibody-based therapies for oncological diseases. The company's developmental pipeline features several promising candidates. A primary focus is APX005M, a humanized agonist antibody currently in Phase II clinical trials. This therapeutic agent is being explored for its efficacy against a variety of solid tumors, including melanoma, esophageal and gastroesophageal junction cancers, sarcoma, and rectal and ovarian malignancies, often in conjunction with other established treatments like immunotherapy, chemotherapy, radiation therapy, and cancer vaccines. Additionally, Apexigen is progressing APX601, a humanized antagonist antibody, through Phase I/II clinical trials for numerous tumor indications. Rounding out their experimental portfolio is APX801, an NK cell engager engineered to stimulate natural killer cells to eradicate cancerous cells.

Jaar	Winst	Wijzigen
Niet genoeg gegevens voor de verstrekte datums.

Jaar

Winst

Wijzigen

Niet genoeg gegevens voor de verstrekte datums.

Bedrijf	Winst	Winstverschil	Land
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-	US
Argenx SE ARGX.US	$1.95B	-	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	$3.01B	-	BE

Bedrijf

Winst

Winstverschil

Land